Qualifications and Employment History
- BA in Natural Sciences (Part II Genetics), University of Cambridge, 1992.
- Postdoctoral work at London Research Institute, Cancer Research UK, 1996-1999.
- Joined Imperial College in 1999 as Lecturer and head of the Androgen Signalling Group in the Department of Oncology.
- Current position: Professor of Cancer Biology, Non-Clinical Head of Prostate Cancer Research in Department of Surgery & Cancer.
- Mechanisms of androgen receptor action.
- Androgen signalling in development and disease.
- Nuclear receptor coactivators and corepressors.
- Mechanisms of therapy resistance in hormone-dependent cancers.
- Novel therapies for prostate cancer.
- Discovery and validation of biomarkers for prostate cancer.
- Role of microRNAs in androgen signalling.
- BSc in Biomedical Science: Lecturer and Course Lead for Cancer Biology year 2
- Graduate Entry Medical Degree: Theme Lead for MCD (Molecules, Cells & Disease) year 1
- BSc in Biochemistry
- Project supervisor for MBBS BSc projects
Postgraduate Taught Courses
- MSc Molecular Medicine
- MRes Cancer Biology
- MSc Human Reproduction
- PhD project supervisor
- Masters project supervisor for MRes Cancer Biology, MSc Human Reproduction, MRes Biomedical Sciences, MSc Molecualr Medicine
- MSc Human Reproduction
Other College roles
Member of the 3Rs committee (College)
Member of the Postgraduate Education Committee for Surgery & Cancer
Member of the Academic Opportunities Committee for Surgery & Cancer
Member of the Student Withdrawals/Appeal panel (College)
Collaborators and External Committees
Please see "Research" tab above
Bevan CL, 2016, WOMEN IN CANCER PROFILE: A gender agenda?, Endocr Relat Cancer, Vol:23, Pages:P5-P8
et al., 2017, A novel role for GSK3 beta as a modulator of Drosha microprocessor activity and MicroRNA biogenesis, Nucleic Acids Research, Vol:45, ISSN:0305-1048, Pages:2809-2828
Leach DA, Powell SM, Bevan CL, 2016, New roles for nuclear receptors in prostate cancer, Endocrine-related Cancer, Vol:23, ISSN:1351-0088, Pages:T85-T108
et al., 2016, Amplification-Free Detection of Circulating microRNA Biomarkers from Body Fluids Based on Fluorogenic Oligonucleotide-Templated Reaction between Engineered Peptide Nucleic Acid Probes: Application to Prostate Cancer Diagnosis, Analytical Chemistry, Vol:88, ISSN:0003-2700, Pages:8091-8098
et al., 2014, Engineered repressors are potent inhibitors of androgen receptor activity, Oncotarget, Vol:5, ISSN:1949-2553, Pages:959-969
et al., 2013, Visualising Androgen Receptor Activity in Male and Female Mice, PLOS One, Vol:8, ISSN:1932-6203
et al., 2013, Circulating microRNAs as potential new biomarkers for prostate cancer, British Journal of Cancer, Vol:108, ISSN:0007-0920, Pages:1925-1930
et al., 2012, Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer, Human Molecular Genetics, Vol:21, ISSN:0964-6906, Pages:3112-3127
et al., 2011, FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth, Cancer Research, Vol:71, ISSN:0008-5472, Pages:914-924
et al., 2007, Prohibitin, a protein downregulated by androgens, represses androgen receptor activity, Oncogene, Vol:26, ISSN:0950-9232, Pages:1757-1768
Brooke GN, Parker MG, Bevan CL, 2008, Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression, Oncogene, Vol:27, ISSN:0950-9232, Pages:2941-2950